Wishka_2006_J.Med.Chem_49_4425

Reference

Title : Discovery of N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]furo[2,3-c]pyridine-5-carboxamide, an agonist of the alpha7 nicotinic acetylcholine receptor, for the potential treatment of cognitive deficits in schizophrenia: synthesis and structure--activity relationship - Wishka_2006_J.Med.Chem_49_4425
Author(s) : Wishka DG , Walker DP , Yates KM , Reitz SC , Jia S , Myers JK , Olson KL , Jacobsen EJ , Wolfe ML , Groppi VE , Hanchar AJ , Thornburgh BA , Cortes-Burgos LA , Wong EH , Staton BA , Raub TJ , Higdon NR , Wall TM , Hurst RS , Walters RR , Hoffmann WE , Hajos M , Franklin S , Carey G , Gold LH , Cook KK , Sands SB , Zhao SX , Soglia JR , Kalgutkar AS , Arneric SP , Rogers BN
Ref : Journal of Medicinal Chemistry , 49 :4425 , 2006
Abstract :

N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]furo[2,3-c]pyridine-5-carboxamide (14, PHA-543,613), a novel agonist of the alpha7 neuronal nicotinic acetylcholine receptor (alpha7 nAChR), has been identified as a potential treatment of cognitive deficits in schizophrenia. Compound 14 is a potent and selective alpha7 nAChR agonist with an excellent in vitro profile. The compound is characterized by rapid brain penetration and high oral bioavailability in rat and demonstrates in vivo efficacy in auditory sensory gating and, in an in vivo model to assess cognitive performance, novel object recognition.

PubMedSearch : Wishka_2006_J.Med.Chem_49_4425
PubMedID: 16821801

Related information

Citations formats

Wishka DG, Walker DP, Yates KM, Reitz SC, Jia S, Myers JK, Olson KL, Jacobsen EJ, Wolfe ML, Groppi VE, Hanchar AJ, Thornburgh BA, Cortes-Burgos LA, Wong EH, Staton BA, Raub TJ, Higdon NR, Wall TM, Hurst RS, Walters RR, Hoffmann WE, Hajos M, Franklin S, Carey G, Gold LH, Cook KK, Sands SB, Zhao SX, Soglia JR, Kalgutkar AS, Arneric SP, Rogers BN (2006)
Discovery of N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]furo[2,3-c]pyridine-5-carboxamide, an agonist of the alpha7 nicotinic acetylcholine receptor, for the potential treatment of cognitive deficits in schizophrenia: synthesis and structure--activity relationship
Journal of Medicinal Chemistry 49 :4425

Wishka DG, Walker DP, Yates KM, Reitz SC, Jia S, Myers JK, Olson KL, Jacobsen EJ, Wolfe ML, Groppi VE, Hanchar AJ, Thornburgh BA, Cortes-Burgos LA, Wong EH, Staton BA, Raub TJ, Higdon NR, Wall TM, Hurst RS, Walters RR, Hoffmann WE, Hajos M, Franklin S, Carey G, Gold LH, Cook KK, Sands SB, Zhao SX, Soglia JR, Kalgutkar AS, Arneric SP, Rogers BN (2006)
Journal of Medicinal Chemistry 49 :4425